Table 2 Demography of study population and medications used after first time PCI
Variable | Study group | P value | |||
|---|---|---|---|---|---|
Control (N = 359) | DM alone (N = 178) | HT alone (N = 382) | DM and HT (N = 315) | ||
Gender | <0.01 | ||||
F | 61 (17.0%) | 44 (24.7%) | 110 (28.8%) | 110 (34.9%) | |
M | 298 (83.0%) | 134 (75.3%) | 272 (71.2%) | 205 (65.1%) | |
CKD | <0.01 | ||||
No | 318 (88.6%) | 132 (74.2%) | 304 (79.6%) | 196 (62.2%) | |
Yes | 41 (11.4%) | 46 (25.8%) | 78 (20.4%) | 119 (37.8%) | |
Hypercholesterolemia | <0.01 | ||||
No | 145 (40.4%) | 98 (55.1%) | 145 (38.0%) | 156 (49.5%) | |
Yes | 214 (59.6%) | 80 (44.9%) | 237 (62.0%) | 159 (50.5%) | |
Current smoker | <0.01 | ||||
No | 192 (53.5%) | 132 (74.2%) | 241 (63%) | 224 (71.1%) | |
Yes | 167 (46.5%) | 46 (25.8%) | 141 (37.0%) | 91 (28.9%) | |
Previous MI | <0.01 | ||||
No | 209 (58.2%) | 98 (55.1%) | 278 (72.7%) | 222 (70.5%) | |
Yes | 150 (41.8%) | 80 (44.9%) | 104 (27.2%) | 93 (29.5%) | |
Stroke history | 0.09 | ||||
No | 347 (96.7%) | 164 (92.1%) | 357 (93.5%) | 293 (93.0%) | |
Yes | 12 (3.3%) | 14 (7.9%) | 25 (6.5%) | 22 (7.0%) | |
CABG history | 0.67 | ||||
No | 358 (99.7%) | 176 (98.9%) | 380 (99.5%) | 313 (99.4%) | |
Yes | 1 (0.3%) | 2 (1.1%) | 2 (0.5%) | 2 (0.6%) | |
Asprin | 0.25 | ||||
No | 24 (6.7%) | 21 (11.8%) | 34 (8.9%) | 26 (8.3%) | |
Yes | 335 (93.3%) | 157 (88.2%) | 348 (91.1%) | 289 (91.8%) | |
P2Y12 inhibitors | 0.66 | ||||
No | 65 (18.1%) | 35 (19.7%) | 64 (16.8%) | 49 (15.6%) | |
Yes | 294 (81.9%) | 143 (80.3%) | 318 (83.3%) | 266 (84.4%) | |
Diuretics | 0.01 | ||||
No | 296 (82.5%) | 131 (73.6%) | 300 (78.5%) | 229 (72.7%) | |
Yes | 63 (17.6%) | 47 (26.4%) | 82 (21.5%) | 86 (27.3%) | |
BB | 0.10 | ||||
No | 213 (59.3%) | 107 (60.1%) | 213 (55.8%) | 160 (50.8%) | |
Yes | 146 (40.7%) | 71 (39.9%) | 169 (44.2%) | 155 (49.2%) | |
CCB | <0.01 | ||||
No | 294 (81.9%) | 126 (70.8%) | 223 (58.4%) | 197 (62.5%) | |
Yes | 65 (18.1%) | 52 (29.2%) | 159 (41.6%) | 118 (37.5%) | |
ACEI | <0.01 | ||||
No | 255 (71.0%) | 127 (71.4%) | 310 (81.2%) | 254 (80.6%) | |
Yes | 104 (29.0%) | 51 (28.7%) | 72 (18.9%) | 61 (19.4%) | |
ARB | <0.01 | ||||
No | 316 (88.0%) | 159 (89.3%) | 267 (69.9%) | 211 (67.0%) | |
Yes | 43 (12.0%) | 19 (10.7%) | 115 (30.1%) | 104 (33.0%) | |
Statin | <0.01 | ||||
No | 232 (64.6%) | 134 (75.3%) | 214 (56.0%) | 210 (66.7%) | |
Yes | 127 (35.4%) | 44 (24.7%) | 168 (44.0%) | 105 (33.3%) | |
Fibrate | 0.08 | ||||
No | 337 (93.9%) | 170 (95.5%) | 355 (92.9%) | 283 (89.8%) | |
Yes | 22 (6.1%) | 8 (4.5%) | 27 (7.1%) | 32 (10.2%) | |